Epidemiology and health burden of infective endocarditis: a comparative analysis of Australian vs global trends from 1990 to 2021
Open Access
- 1 October 2026
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
Abstract
Background: Infective endocarditis (IE) is an uncommon but life‐threatening disease with evolving patient risk profiles and management strategies. However, its impact on the Australian healthcare system has not been described. Aims: To quantify the healthcare burden of IE in Australia over time in the past three decades and compare outcomes with global and high‐income settings. Methods: Data extracted from Global Burden of Disease 2021 included IE prevalence, mortality, disability‐adjusted life years (DALY), and heart failure (HF) attributed to IE from 1990 to 2021. Each metric was further indexed to age‐adjusted prevalence and expressed as summary rates per 100 IE cases (e.g. prevalence‐adjusted mortality rate), and were stratified by geographical groups (Australia, Global and High‐Income), sex and 5‐year age groups. Results: Between 1990 and 2021, 8 563 131 IE cases were reported worldwide, with 0.74% occurring in Australia. In Australia, age‐adjusted prevalence rates of IE (AAPR) quadrupled over time (AAPR AUS : 2.63–10.18 per 100 000 persons), whilst prevalence‐adjusted mortality rates (PAMR) and disability rates (PADR) declined (PAMR AUS : 18.6–11.25 deaths per hundred cases; PADR AUS : 440–244 DALY per hundred cases). Australia reported a growth in prevalence‐adjusted heart failure rates (PAHR AUS : 68.4–86.8 HF per hundred IE cases). Across all geographical groups, including Australia, bimodal peaks in mortality and disability affected middle‐aged (40–64 years) and elderly populations (≥75 years). IE prevalence was relatively even between sexes; males experienced higher IE mortality and disability, while females experienced a greater burden of heart failure. Conclusions: Australia's IE profile is distinct, with a sharper rise in prevalence and IE‐associated heart failure, despite declining mortality and disability. These findings suggest improved survival but increasing chronic morbidity, underscoring the need for enhanced post‐acute care models and further research to explore underlying drivers, including evolving risk factors, healthcare access and long‐term cardiac outcomes.Keywords
This publication has 40 references indexed in Scilit:
- A Comprehensive Approach to Managing Methamphetamine-Associated CardiomyopathyAmerican Journal of Cardiovascular Drugs, 2022
- Impact of referral bias on prognostic studies outcomes: insights from a population-based cohort study on infective endocarditisAnnals of Epidemiology, 2021
- Infective Endocarditis in the Intravenous Drug Use Population at a Tertiary Hospital in Melbourne, AustraliaHeart, Lung and Circulation, 2020
- Severity of Presentation, Not Sex, Increases Risk of Surgery for Infective EndocarditisThe Annals of Thoracic Surgery, 2019
- Recommendations on nuclear and multimodality imaging in IE and CIED infectionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- The Current Epidemiology of Injecting Drug Use-Associated Infective Endocarditis in Victoria, Australia in the Midst of Increasing Crystal Methamphetamine UseHeart, Lung and Circulation, 2017
- The Cardiac Complications of MethamphetaminesHeart, Lung and Circulation, 2016
- Infective EndocarditisHeart, Lung and Circulation, 2014
- Association Between Valvular Surgery and Mortality Among Patients With Infective Endocarditis Complicated by Heart FailureJAMA, 2011
- Surgical Management and Mid-term Outcomes of 108 Patients with Infective EndocarditisHeart, Lung and Circulation, 2011